Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) Latest Company News

Oct 28, 2026, 11:00 UTC
Dongcheng Pharmaceutical reported first-three-quarter 2026 revenue of 1.935 billion yuan, down 5.29% year over year, and attributable net profit of 164 million yuan, up 9.71%.
Source:
- finance.sina.cn
Oct 28, 2026, 11:00 UTC
Dongcheng Pharmaceutical reported third-quarter 2026 revenue of 626 million yuan, down 5.05% year over year, and attributable net profit of 69.85 million yuan, up 15.52%.
Source:
- finance.sina.cn
Oct 15, 2026, 03:17 UTC
Dongcheng Pharmaceutical indirectly wholly owns newly established Guangxi Andike Pharmaceutical Co., Ltd., which has registered capital of RMB 10 million and a business scope including drug production.
Source:
- finance.sina.cn
Oct 14, 2026, 11:44 UTC
Dongcheng Pharmaceutical’s board approved convening its second extraordinary shareholders’ meeting of 2026.
Source:
- finance.sina.cn
Oct 14, 2026, 11:44 UTC
Dongcheng Pharmaceutical’s board approved changing the company’s business scope and revising its articles of association, subject to shareholder approval.
Source:
- finance.sina.cn
Oct 14, 2026, 11:44 UTC
Dongcheng Pharmaceutical’s board approved terminating the proposed Hong Kong listing of a subsidiary.
Source:
- finance.sina.cn
Oct 14, 2026, 11:44 UTC
Dongcheng Pharmaceutical’s board approved a related-party transaction to acquire minority shareholders’ equity in a controlled subsidiary, subject to shareholder approval.
Source:
- finance.sina.cn
Sep 9, 2026, 10:42 UTC
Yantai Dongcheng North Pharmaceutical, a wholly-owned subsidiary of Dongcheng Pharmaceutical, received acceptance of its marketing authorization application for Bemiparin Sodium Injection from China's National Medical Products Administration on September 9, 2026.
Source:
- finance.sina.cn
Sep 2, 2026, 09:03 UTC
Dongcheng Pharmaceutical announced that as of August 31, 2026, it had repurchased 7.3995 million shares (0.90% of total shares) for a total of 100 million yuan under its ongoing buyback program.
Source:
- finance.sina.cn
Aug 24, 2026, 10:35 UTC
Dongcheng Pharmaceutical's wholly-owned subsidiary Andike signed equity transfer agreements to acquire 100% of Kunming Cyclotron and 100% of Sichuan Cyclotron for RMB 40.2 million and RMB 40 million respectively, and to sell its 45% stake in Guangdong Cyclotron for RMB 121 million.
Source:
- finance.sina.cn
Aug 14, 2026, 08:15 UTC
Dongcheng Pharmaceutical's subsidiary Andike received a radioactive drug production license from Shanxi Provincial Drug Administration, allowing its Shanxi Jinzhong nuclear medicine production center to begin operations, producing fludeoxyglucose F-18 injection.
Source:
- finance.sina.cn
Aug 6, 2026, 11:55 UTC
Dongcheng Pharmaceutical announced that its marketing application for the API bemiparin sodium has been accepted by the National Medical Products Administration.
Source:
- finance.sina.cn

002675.SZ

Dongcheng Pharmaceutical reported first-three-quarter 2026 revenue of 1.935 billion yuan, down 5.29% year over year, and attributable net profit of 164 million yuan, up 9.71%.

Dongcheng Pharmaceutical reported third-quarter 2026 revenue of 626 million yuan, down 5.05% year over year, and attributable net profit of 69.85 million yuan, up 15.52%.

Dongcheng Pharmaceutical indirectly wholly owns newly established Guangxi Andike Pharmaceutical Co., Ltd., which has registered capital of RMB 10 million and a business scope including drug production.

Dongcheng Pharmaceutical’s board approved convening its second extraordinary shareholders’ meeting of 2026.

Dongcheng Pharmaceutical’s board approved changing the company’s business scope and revising its articles of association, subject to shareholder approval.

Dongcheng Pharmaceutical’s board approved terminating the proposed Hong Kong listing of a subsidiary.

Dongcheng Pharmaceutical’s board approved a related-party transaction to acquire minority shareholders’ equity in a controlled subsidiary, subject to shareholder approval.

Yantai Dongcheng North Pharmaceutical, a wholly-owned subsidiary of Dongcheng Pharmaceutical, received acceptance of its marketing authorization application for Bemiparin Sodium Injection from China's National Medical Products Administration on September 9, 2026.

Dongcheng Pharmaceutical announced that as of August 31, 2026, it had repurchased 7.3995 million shares (0.90% of total shares) for a total of 100 million yuan under its ongoing buyback program.

Dongcheng Pharmaceutical's wholly-owned subsidiary Andike signed equity transfer agreements to acquire 100% of Kunming Cyclotron and 100% of Sichuan Cyclotron for RMB 40.2 million and RMB 40 million respectively, and to sell its 45% stake in Guangdong Cyclotron for RMB 121 million.

Dongcheng Pharmaceutical's subsidiary Andike received a radioactive drug production license from Shanxi Provincial Drug Administration, allowing its Shanxi Jinzhong nuclear medicine production center to begin operations, producing fludeoxyglucose F-18 injection.

Dongcheng Pharmaceutical announced that its marketing application for the API bemiparin sodium has been accepted by the National Medical Products Administration.